LPL Receptor

Lysophospholipid (LPL) receptor modulators here act mainly on sphingosine-1-phosphate (S1P) signaling. Lysophospholipid receptors are G protein-coupled receptors for lysophosphatidic acid (LPA) and S1P. A 2010 nomenclature review listed five LPA receptors with a proposed sixth (LPA1 to LPA6) and five S1P receptors. Ceralifimod, S1P1 agonist 1 and (S)-FTY720-phosphonate are agonists at S1P receptor 1, which controls lymphocyte exit from lymphoid organs. Other compounds change the amount of ligand available to the receptors. SLF1081851 and SLF80821178 inhibit spinster homolog 2 (Spns2), a transporter that exports S1P from cells. Spns2 was identified in 2009 as a sphingolipid transporter needed for migration of zebrafish myocardial precursors. S1PL-IN-1 inhibits S1P lyase, the enzyme that degrades S1P irreversibly inside cells.

9 Items

  • Ceralifimod
    Cat. No.
    A61152

    Ceralifimod

    Synonyms: ONO-4641

    Ceralifimod is a potent and selective agonist for the sphingosine 1-phosphate receptors 1 and 5, exhibiting effective EC50 values of 27.3 pM and 334 pM for human S1P receptor 1 and 5, respectively. This compound is primarily utilized in research applications investigating immune modulation and cardiovascular disease. Its targeted mechanism provides valuable insights into receptor signaling pathways relevant to inflammation and tissue homeostasis.

    1 mg
    $25.00
    2 mg
    $40.00
    All 6 sizes
  • S1P1 agonist 1
    Cat. No.
    A61168

    S1P1 agonist 1

    S1P1 Agonist 1 targets the sphingosine-1-phosphate receptor 1 (S1P1) as an agonist, exerting significant immunomodulatory effects. This compound plays a crucial role in modulating immune responses and inflammation, making it valuable for research in immunology and related fields. S1P1 Agonist 1 is instrumental in studies exploring the therapeutic potential of S1P1 activation in various diseases.

    2 mg
    $55.00
    5 mg
    $115.00
    All 5 sizes
  • (S)-FTY720-phosphonate
    Cat. No.
    A61172

    (S)-FTY720-phosphonate

    (S)-FTY720-phosphonate is a selective agonist of the S1P receptor 1 (S1PR1). This compound is primarily employed in research related to acute inflammatory diseases, including but not limited to acute lung injury. By activating S1PR1, (S)-FTY720-phosphonate may facilitate studies on its role in immune response modulation and tissue repair mechanisms.

    1 mg
    $345.00
    5 mg
    $900.00
    All 4 sizes
  • GSK2018682 hydrochloride
    Cat. No.
    A61196

    GSK2018682 hydrochloride

    GSK2018682 hydrochloride is a specific agonist for the sphingosine-1-phosphate receptors S1P1 and S1P5, exhibiting pEC50 values of 7.7 and 7.2, respectively. It shows no agonist activity toward the S1P2, S1P3, or S1P4 receptors. This compound is primarily utilized in research investigating multiple sclerosis and related neurological disorders, offering insights into the modulation of immune responses and vascular integrity.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • CS-0777-P
    Cat. No.
    A61204

    CS-0777-P

    CS-0777-P is a potent and selective agonist of the sphingosine 1-phosphate receptor 1 (S1P1). It displays approximately 320-fold higher activity for human S1P1 compared to S1P3, with an EC50 of 1.1 nM. Biological studies indicate its capability to significantly reduce peripheral blood lymphocyte counts and exert immunosuppressive effects in experimental autoimmune encephalomyelitis models in rats. Pharmacokinetic analysis reveals swift lymphocyte count reductions after oral administration, highlighting CS-0777-P's potential as a therapeutic candidate for multiple sclerosis, currently under clinical investigation.

    25 mg
    $2,790.00
    50 mg
    $3,590.00
    All 3 sizes
  • AUY 954 hydrochloride
    Cat. No.
    A61213

    AUY 954 hydrochloride

    AUY 954 hydrochloride is a potent and selective agonist of the sphingosine-1-phosphate (S1P(1)) receptor, exhibiting significant immunomodulatory properties. It induces a notable and reversible decrease in circulating lymphocytes following oral administration. In preclinical studies, AUY 954 hydrochloride has shown efficacy in prolonging cardiac allograft survival in conjunction with RAD001, as well as effectively preventing experimental autoimmune neuritis in rat models. This compound holds promising therapeutic potential for various autoimmune conditions.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • NSC12404
    Cat. No.
    A61217

    NSC12404

    NSC12404 is a selective agonist for the lysophosphatidic acid receptor 2 (LPA2). This compound exhibits weak but specific activity, making it a valuable tool for studying LPA2 receptor signaling pathways. Its applications in research include investigating the role of LPA2 in cellular processes such as proliferation, migration, and differentiation.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Zectivimod
    Cat. No.
    A61228

    Zectivimod

    Zectivimod is a sphingosine-1-phosphate receptor agonist that plays a crucial role in modulating immune responses. It exhibits significant biological activity in the context of autoimmune diseases, chronic inflammatory conditions, and immunoregulation disorders. This compound is valuable for research aimed at understanding the underlying mechanisms of immune system modulation and the development of therapeutic strategies.

    5 mg
    $345.00
    10 mg
    $590.00
    All 5 sizes
  • AUY954
    Cat. No.
    A61254

    AUY954

    AUY954 is a selective agonist of the sphingosine-1-phosphate receptor 1, exhibiting an EC50 of 1.2 nM for the human S1P1 receptor. This compound demonstrates significant biological activity in modulating immune responses and is primarily utilized in research focused on experimental autoimmune neuritis. AUY954's selective action makes it a valuable tool for studying the role of sphingosine-1-phosphate signaling in various autoimmune conditions.

    0.5 mg
    $135.00
    1 mg
    $220.00
    All 3 sizes

9 Items

Added to your cart

View Cart Checkout

    Loading...